Share Price and Basic Stock Data
Last Updated: November 22, 2025, 11:01 am
| PEG Ratio | -1.99 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Chemcrux Enterprises Ltd operates in the specialty chemicals sector, focusing on various chemical products. The company’s share price stood at ₹114, with a market capitalization of ₹169 Cr. Over the last few years, Chemcrux has experienced fluctuating revenue trends. In FY 2022, total sales reached ₹95.27 Cr, slightly declining to ₹95.15 Cr in FY 2023. However, the anticipated revenue for FY 2024 is ₹78.47 Cr, reflecting a notable decrease. A detailed quarterly analysis reveals that the highest sales figure was recorded in September 2022 at ₹27.74 Cr, while the lowest was in September 2023, which plummeted to ₹15.84 Cr. The company’s cash conversion cycle (CCC) stood at 137.76 days, indicating potential inefficiencies in working capital management compared to sector averages. The company’s sales performance is critical as it grapples with maintaining revenue stability amidst competitive pressures and market fluctuations.
Profitability and Efficiency Metrics
The profitability of Chemcrux Enterprises has shown variability, with the operating profit margin (OPM) recorded at 12.15% in FY 2025, down from 21.74% in FY 2022. The operating profit for FY 2025 was reported at ₹9.07 Cr, while the net profit for the same period stood at ₹4.19 Cr, reflecting a decline from ₹14.86 Cr in FY 2022. The return on equity (ROE) was reported at 5.36%, which is relatively low compared to industry standards, signaling a potential area for improvement. The interest coverage ratio (ICR) of 6.14x indicates that the company can comfortably cover its interest obligations, a positive sign for financial stability. However, the declining trend in profitability metrics raises concerns regarding cost management and pricing strategies, necessitating a review of operational efficiencies to enhance margins in the future.
Balance Sheet Strength and Financial Ratios
Chemcrux Enterprises reported zero borrowings, reflecting a conservative approach to debt management, which is a strength in its balance sheet. The company’s total equity stood at ₹50.39 per share, with a price-to-book value (P/BV) ratio of 2.00x. This indicates that the stock is trading at a premium compared to its book value, which may suggest investor confidence in future growth prospects. However, the current ratio of 2.31 and quick ratio of 1.81 reflect a solid liquidity position, allowing the company to meet its short-term obligations effectively. The decline in net profit margin from 15.08% in FY 2023 to 5.58% in FY 2025 raises red flags about the company’s ability to convert sales into actual profit. Furthermore, the asset turnover ratio of 0.59% indicates that the company may not be efficiently utilizing its assets to generate revenue, which is another area for potential improvement.
Shareholding Pattern and Investor Confidence
The shareholding structure of Chemcrux Enterprises indicates a strong promoter holding of 72.92%, which has remained stable over recent quarters. This substantial ownership by promoters may instill confidence among investors regarding the company’s strategic direction and governance. The public shareholding stood at 27.07%, with a total of 23,478 shareholders as of March 2025, showing a gradual decline from 30,266 in March 2023. The consistent promoter stake suggests a long-term commitment to the company’s growth, although the declining number of public shareholders could raise concerns about market interest. The absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) indicates limited institutional backing, which may affect liquidity and market perception. Overall, the shareholding pattern reflects a strong commitment from promoters but a need for broader market engagement to enhance investor confidence.
Outlook, Risks, and Final Insight
The outlook for Chemcrux Enterprises appears mixed, with strengths in its debt-free status and a strong promoter holding. However, the declining revenue and profitability metrics pose significant risks. The company must address its operational efficiency, particularly in managing its cash conversion cycle and enhancing profit margins. The presence of zero borrowings provides a cushion against financial distress, but the declining net profit margin and asset turnover ratio suggest a need for strategic recalibration. Moving forward, Chemcrux needs to focus on improving revenue stability and operational efficiencies to attract institutional investors and enhance shareholder value. If the company can successfully navigate these challenges, it may regain momentum in the specialty chemicals sector; otherwise, it risks further erosion of investor sentiment and market position.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Chemcrux Enterprises Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 425 Cr. | 46.1 | 86.7/42.6 | 26.4 | 20.5 | 0.87 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 35.2 Cr. | 71.7 | 103/56.0 | 16.8 | 89.6 | 1.40 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 46.2 Cr. | 680 | 988/600 | 21.3 | 697 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,679 Cr. | 81.2 | 111/78.0 | 24.4 | 22.0 | 0.62 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 656 Cr. | 263 | 453/241 | 23.6 | 93.8 | 0.95 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 12,884.24 Cr | 741.86 | 63.68 | 182.93 | 0.42% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 26.66 | 26.90 | 27.74 | 20.50 | 20.01 | 22.29 | 15.84 | 21.81 | 18.54 | 17.11 | 17.76 | 19.42 | 15.97 |
| Expenses | 20.24 | 21.38 | 21.94 | 15.47 | 14.90 | 18.43 | 13.50 | 17.43 | 15.92 | 15.05 | 15.40 | 16.73 | 14.03 |
| Operating Profit | 6.42 | 5.52 | 5.80 | 5.03 | 5.11 | 3.86 | 2.34 | 4.38 | 2.62 | 2.06 | 2.36 | 2.69 | 1.94 |
| OPM % | 24.08% | 20.52% | 20.91% | 24.54% | 25.54% | 17.32% | 14.77% | 20.08% | 14.13% | 12.04% | 13.29% | 13.85% | 12.15% |
| Other Income | 0.10 | 0.24 | 0.32 | 0.31 | 0.18 | 0.18 | 0.24 | 0.56 | 0.35 | 0.39 | 0.26 | 0.61 | 0.28 |
| Interest | 0.06 | 0.15 | 0.13 | 0.07 | 0.47 | 0.31 | 0.21 | 0.17 | 0.13 | 0.13 | 0.33 | 0.60 | 0.58 |
| Depreciation | 0.41 | 0.44 | 0.48 | 0.54 | 0.58 | 0.57 | 0.58 | 0.58 | 0.55 | 0.56 | 0.73 | 0.92 | 0.91 |
| Profit before tax | 6.05 | 5.17 | 5.51 | 4.73 | 4.24 | 3.16 | 1.79 | 4.19 | 2.29 | 1.76 | 1.56 | 1.78 | 0.73 |
| Tax % | 25.12% | 25.92% | 26.86% | 24.31% | 31.13% | 26.27% | 30.17% | 36.75% | 3.49% | 29.55% | 26.28% | 25.84% | 35.62% |
| Net Profit | 4.53 | 3.83 | 4.03 | 3.58 | 2.92 | 2.33 | 1.24 | 2.66 | 2.21 | 1.24 | 1.15 | 1.33 | 0.47 |
| EPS in Rs | 3.06 | 2.59 | 2.72 | 2.42 | 1.97 | 1.57 | 0.84 | 1.80 | 1.49 | 0.84 | 0.78 | 0.90 | 0.32 |
Last Updated: May 31, 2025, 6:32 am
Below is a detailed analysis of the quarterly data for Chemcrux Enterprises Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 15.97 Cr.. The value appears to be declining and may need further review. It has decreased from 19.42 Cr. (Dec 2024) to 15.97 Cr., marking a decrease of 3.45 Cr..
- For Expenses, as of Mar 2025, the value is 14.03 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 16.73 Cr. (Dec 2024) to 14.03 Cr., marking a decrease of 2.70 Cr..
- For Operating Profit, as of Mar 2025, the value is 1.94 Cr.. The value appears to be declining and may need further review. It has decreased from 2.69 Cr. (Dec 2024) to 1.94 Cr., marking a decrease of 0.75 Cr..
- For OPM %, as of Mar 2025, the value is 12.15%. The value appears to be declining and may need further review. It has decreased from 13.85% (Dec 2024) to 12.15%, marking a decrease of 1.70%.
- For Other Income, as of Mar 2025, the value is 0.28 Cr.. The value appears to be declining and may need further review. It has decreased from 0.61 Cr. (Dec 2024) to 0.28 Cr., marking a decrease of 0.33 Cr..
- For Interest, as of Mar 2025, the value is 0.58 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.60 Cr. (Dec 2024) to 0.58 Cr., marking a decrease of 0.02 Cr..
- For Depreciation, as of Mar 2025, the value is 0.91 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.92 Cr. (Dec 2024) to 0.91 Cr., marking a decrease of 0.01 Cr..
- For Profit before tax, as of Mar 2025, the value is 0.73 Cr.. The value appears to be declining and may need further review. It has decreased from 1.78 Cr. (Dec 2024) to 0.73 Cr., marking a decrease of 1.05 Cr..
- For Tax %, as of Mar 2025, the value is 35.62%. The value appears to be increasing, which may not be favorable. It has increased from 25.84% (Dec 2024) to 35.62%, marking an increase of 9.78%.
- For Net Profit, as of Mar 2025, the value is 0.47 Cr.. The value appears to be declining and may need further review. It has decreased from 1.33 Cr. (Dec 2024) to 0.47 Cr., marking a decrease of 0.86 Cr..
- For EPS in Rs, as of Mar 2025, the value is 0.32. The value appears to be declining and may need further review. It has decreased from 0.90 (Dec 2024) to 0.32, marking a decrease of 0.58.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 3:40 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 15.61 | 19.60 | 20.09 | 27.43 | 31.45 | 55.27 | 57.45 | 53.33 | 95.27 | 95.15 | 78.47 | 70.25 | 70.69 |
| Expenses | 14.05 | 17.39 | 16.94 | 23.98 | 26.72 | 41.09 | 42.67 | 40.77 | 74.56 | 73.69 | 65.10 | 61.18 | 62.80 |
| Operating Profit | 1.56 | 2.21 | 3.15 | 3.45 | 4.73 | 14.18 | 14.78 | 12.56 | 20.71 | 21.46 | 13.37 | 9.07 | 7.89 |
| OPM % | 9.99% | 11.28% | 15.68% | 12.58% | 15.04% | 25.66% | 25.73% | 23.55% | 21.74% | 22.55% | 17.04% | 12.91% | 11.16% |
| Other Income | 0.03 | 0.06 | 0.07 | 0.31 | 0.29 | -0.30 | 0.90 | 0.84 | 1.00 | 1.05 | 1.18 | 1.53 | 2.30 |
| Interest | 0.45 | 0.42 | 0.26 | 0.35 | 0.31 | 0.28 | 0.32 | 0.15 | 0.17 | 0.82 | 0.83 | 1.64 | 2.22 |
| Depreciation | 0.50 | 0.55 | 0.50 | 0.55 | 0.67 | 1.26 | 1.18 | 1.20 | 1.59 | 2.04 | 2.29 | 3.13 | 3.74 |
| Profit before tax | 0.64 | 1.30 | 2.46 | 2.86 | 4.04 | 12.34 | 14.18 | 12.05 | 19.95 | 19.65 | 11.43 | 5.83 | 4.23 |
| Tax % | 31.25% | 34.62% | 29.27% | 47.55% | 41.58% | 24.55% | 24.96% | 25.81% | 25.51% | 26.92% | 26.16% | 28.13% | |
| Net Profit | 0.43 | 0.85 | 1.74 | 1.50 | 2.36 | 9.32 | 10.64 | 8.93 | 14.86 | 14.36 | 8.44 | 4.19 | 3.18 |
| EPS in Rs | 0.80 | 1.57 | 3.22 | 1.01 | 1.59 | 6.30 | 7.19 | 6.03 | 10.03 | 9.70 | 5.70 | 2.83 | 2.15 |
| Dividend Payout % | 0.00% | 5.29% | 2.59% | 8.23% | 5.23% | 2.65% | 18.57% | 11.06% | 19.93% | 20.63% | 17.55% | 35.35% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 97.67% | 104.71% | -13.79% | 57.33% | 294.92% | 14.16% | -16.07% | 66.41% | -3.36% | -41.23% | -50.36% |
| Change in YoY Net Profit Growth (%) | 0.00% | 7.03% | -118.50% | 71.13% | 237.58% | -280.75% | -30.23% | 82.48% | -69.77% | -37.86% | -9.13% |
Chemcrux Enterprises Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 4% |
| 3 Years: | -10% |
| TTM: | -5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | -17% |
| 3 Years: | -35% |
| TTM: | -52% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | -34% |
| 1 Year: | -45% |
| Return on Equity | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 17% |
| 3 Years: | 13% |
| Last Year: | 5% |
Last Updated: September 5, 2025, 2:56 pm
No data available for the Balance Sheet data table.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 59.63 | 42.46 | 65.22 | 56.69 | 74.28 | 71.52 | 59.79 | 22.65 | 72.33 | 51.56 | 71.17 | 63.44 |
| Inventory Days | 159.97 | 104.29 | 74.71 | 105.14 | 111.70 | 71.92 | 84.82 | 137.46 | 92.33 | 124.92 | 99.63 | 127.16 |
| Days Payable | 146.63 | 73.69 | 38.26 | 54.75 | 131.52 | 75.76 | 46.42 | 15.85 | 92.57 | 71.19 | 70.84 | 52.84 |
| Cash Conversion Cycle | 72.96 | 73.06 | 101.68 | 107.07 | 54.46 | 67.67 | 98.19 | 144.26 | 72.09 | 105.28 | 99.96 | 137.76 |
| Working Capital Days | 8.18 | 8.94 | 21.80 | 34.20 | 43.17 | 47.68 | 52.48 | 67.69 | 37.51 | 67.28 | 55.49 | 50.09 |
| ROCE % | 11.87% | 18.58% | 25.85% | 22.26% | 24.81% | 58.78% | 46.03% | 31.55% | 37.64% | 27.75% | 13.46% | 7.11% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 2.64 | 5.70 | 9.70 |
| Diluted EPS (Rs.) | 2.64 | 5.70 | 9.70 |
| Cash EPS (Rs.) | 4.81 | 7.25 | 11.07 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 50.39 | 48.79 | 44.84 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 50.39 | 48.79 | 44.84 |
| Revenue From Operations / Share (Rs.) | 47.27 | 52.98 | 64.25 |
| PBDIT / Share (Rs.) | 7.24 | 9.82 | 15.20 |
| PBIT / Share (Rs.) | 5.07 | 8.28 | 13.82 |
| PBT / Share (Rs.) | 3.89 | 7.72 | 13.27 |
| Net Profit / Share (Rs.) | 2.64 | 5.70 | 9.70 |
| NP After MI And SOA / Share (Rs.) | 2.64 | 5.70 | 9.70 |
| PBDIT Margin (%) | 15.30 | 18.54 | 23.64 |
| PBIT Margin (%) | 10.72 | 15.62 | 21.50 |
| PBT Margin (%) | 8.22 | 14.56 | 20.64 |
| Net Profit Margin (%) | 5.58 | 10.76 | 15.08 |
| NP After MI And SOA Margin (%) | 5.58 | 10.76 | 15.08 |
| Return on Networth / Equity (%) | 5.24 | 11.68 | 21.62 |
| Return on Capital Employeed (%) | 7.01 | 12.65 | 25.13 |
| Return On Assets (%) | 3.08 | 7.68 | 14.49 |
| Long Term Debt / Equity (X) | 0.37 | 0.29 | 0.18 |
| Total Debt / Equity (X) | 0.55 | 0.35 | 0.23 |
| Asset Turnover Ratio (%) | 0.59 | 0.75 | 0.00 |
| Current Ratio (X) | 2.31 | 3.88 | 3.34 |
| Quick Ratio (X) | 1.81 | 3.23 | 2.54 |
| Inventory Turnover Ratio (X) | 7.60 | 2.25 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 37.84 | 35.07 | 20.62 |
| Dividend Payout Ratio (CP) (%) | 20.80 | 27.60 | 18.06 |
| Earning Retention Ratio (%) | 62.16 | 64.93 | 79.38 |
| Cash Earning Retention Ratio (%) | 79.20 | 72.40 | 81.94 |
| Interest Coverage Ratio (X) | 6.14 | 17.48 | 27.50 |
| Interest Coverage Ratio (Post Tax) (X) | 3.24 | 11.14 | 18.54 |
| Enterprise Value (Cr.) | 189.29 | 402.43 | 448.23 |
| EV / Net Operating Revenue (X) | 2.70 | 5.13 | 4.71 |
| EV / EBITDA (X) | 17.66 | 27.66 | 19.92 |
| MarketCap / Net Operating Revenue (X) | 2.13 | 4.87 | 4.62 |
| Retention Ratios (%) | 62.15 | 64.92 | 79.37 |
| Price / BV (X) | 2.00 | 5.29 | 6.62 |
| Price / Net Operating Revenue (X) | 2.13 | 4.87 | 4.62 |
| EarningsYield | 0.02 | 0.02 | 0.03 |
After reviewing the key financial ratios for Chemcrux Enterprises Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 2.64. This value is below the healthy minimum of 5. It has decreased from 5.70 (Mar 24) to 2.64, marking a decrease of 3.06.
- For Diluted EPS (Rs.), as of Mar 25, the value is 2.64. This value is below the healthy minimum of 5. It has decreased from 5.70 (Mar 24) to 2.64, marking a decrease of 3.06.
- For Cash EPS (Rs.), as of Mar 25, the value is 4.81. This value is within the healthy range. It has decreased from 7.25 (Mar 24) to 4.81, marking a decrease of 2.44.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 50.39. It has increased from 48.79 (Mar 24) to 50.39, marking an increase of 1.60.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 50.39. It has increased from 48.79 (Mar 24) to 50.39, marking an increase of 1.60.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 47.27. It has decreased from 52.98 (Mar 24) to 47.27, marking a decrease of 5.71.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 7.24. This value is within the healthy range. It has decreased from 9.82 (Mar 24) to 7.24, marking a decrease of 2.58.
- For PBIT / Share (Rs.), as of Mar 25, the value is 5.07. This value is within the healthy range. It has decreased from 8.28 (Mar 24) to 5.07, marking a decrease of 3.21.
- For PBT / Share (Rs.), as of Mar 25, the value is 3.89. This value is within the healthy range. It has decreased from 7.72 (Mar 24) to 3.89, marking a decrease of 3.83.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.64. This value is within the healthy range. It has decreased from 5.70 (Mar 24) to 2.64, marking a decrease of 3.06.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 2.64. This value is within the healthy range. It has decreased from 5.70 (Mar 24) to 2.64, marking a decrease of 3.06.
- For PBDIT Margin (%), as of Mar 25, the value is 15.30. This value is within the healthy range. It has decreased from 18.54 (Mar 24) to 15.30, marking a decrease of 3.24.
- For PBIT Margin (%), as of Mar 25, the value is 10.72. This value is within the healthy range. It has decreased from 15.62 (Mar 24) to 10.72, marking a decrease of 4.90.
- For PBT Margin (%), as of Mar 25, the value is 8.22. This value is below the healthy minimum of 10. It has decreased from 14.56 (Mar 24) to 8.22, marking a decrease of 6.34.
- For Net Profit Margin (%), as of Mar 25, the value is 5.58. This value is within the healthy range. It has decreased from 10.76 (Mar 24) to 5.58, marking a decrease of 5.18.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 5.58. This value is below the healthy minimum of 8. It has decreased from 10.76 (Mar 24) to 5.58, marking a decrease of 5.18.
- For Return on Networth / Equity (%), as of Mar 25, the value is 5.24. This value is below the healthy minimum of 15. It has decreased from 11.68 (Mar 24) to 5.24, marking a decrease of 6.44.
- For Return on Capital Employeed (%), as of Mar 25, the value is 7.01. This value is below the healthy minimum of 10. It has decreased from 12.65 (Mar 24) to 7.01, marking a decrease of 5.64.
- For Return On Assets (%), as of Mar 25, the value is 3.08. This value is below the healthy minimum of 5. It has decreased from 7.68 (Mar 24) to 3.08, marking a decrease of 4.60.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.37. This value is within the healthy range. It has increased from 0.29 (Mar 24) to 0.37, marking an increase of 0.08.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.55. This value is within the healthy range. It has increased from 0.35 (Mar 24) to 0.55, marking an increase of 0.20.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.59. It has decreased from 0.75 (Mar 24) to 0.59, marking a decrease of 0.16.
- For Current Ratio (X), as of Mar 25, the value is 2.31. This value is within the healthy range. It has decreased from 3.88 (Mar 24) to 2.31, marking a decrease of 1.57.
- For Quick Ratio (X), as of Mar 25, the value is 1.81. This value is within the healthy range. It has decreased from 3.23 (Mar 24) to 1.81, marking a decrease of 1.42.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.60. This value is within the healthy range. It has increased from 2.25 (Mar 24) to 7.60, marking an increase of 5.35.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 37.84. This value is within the healthy range. It has increased from 35.07 (Mar 24) to 37.84, marking an increase of 2.77.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 20.80. This value is within the healthy range. It has decreased from 27.60 (Mar 24) to 20.80, marking a decrease of 6.80.
- For Earning Retention Ratio (%), as of Mar 25, the value is 62.16. This value is within the healthy range. It has decreased from 64.93 (Mar 24) to 62.16, marking a decrease of 2.77.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 79.20. This value exceeds the healthy maximum of 70. It has increased from 72.40 (Mar 24) to 79.20, marking an increase of 6.80.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 6.14. This value is within the healthy range. It has decreased from 17.48 (Mar 24) to 6.14, marking a decrease of 11.34.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.24. This value is within the healthy range. It has decreased from 11.14 (Mar 24) to 3.24, marking a decrease of 7.90.
- For Enterprise Value (Cr.), as of Mar 25, the value is 189.29. It has decreased from 402.43 (Mar 24) to 189.29, marking a decrease of 213.14.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.70. This value is within the healthy range. It has decreased from 5.13 (Mar 24) to 2.70, marking a decrease of 2.43.
- For EV / EBITDA (X), as of Mar 25, the value is 17.66. This value exceeds the healthy maximum of 15. It has decreased from 27.66 (Mar 24) to 17.66, marking a decrease of 10.00.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.13. This value is within the healthy range. It has decreased from 4.87 (Mar 24) to 2.13, marking a decrease of 2.74.
- For Retention Ratios (%), as of Mar 25, the value is 62.15. This value is within the healthy range. It has decreased from 64.92 (Mar 24) to 62.15, marking a decrease of 2.77.
- For Price / BV (X), as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 5.29 (Mar 24) to 2.00, marking a decrease of 3.29.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.13. This value is within the healthy range. It has decreased from 4.87 (Mar 24) to 2.13, marking a decrease of 2.74.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Chemcrux Enterprises Ltd:
- Net Profit Margin: 5.58%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 7.01% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.24% (Industry Average ROE: 25.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.24
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.81
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 52.8 (Industry average Stock P/E: 63.68)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.55
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 5.58%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | 330, Trivia Complex, Vadodra Gujarat 390007 | celbaroda3821@gmail.com http://www.chemcrux.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Girishkumar C Shah | Executive Chairman |
| Mr. Sanjay Marathe | Managing Director |
| Mr. Vipul Sanghvi | Executive Director |
| Mr. Sidhdhi G Shah | Non Executive Director |
| Mr. Shailesh Patel | Independent Director |
| Mr. Bhanubhai Patel | Independent Director |
| Mr. Nayankumar Shah | Independent Director |
| Mr. Rohit Kothari | Independent Director |